Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9670MR)

This product GTTS-WQ9670MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9670MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4156MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ3562MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ6192MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ13907MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ11583MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ6844MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ5504MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ9081MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW